Study of tezampanel for opioid withdrawal
Part of Mental health clinical trials.
This trial tests if tezampanel can help relieve withdrawal symptoms in people with opioid use disorder who are seeking treatment. Participants must already be in an outpatient addiction program.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with opioid use disorder.
- Your urine drug screen shows opioids at the first two visits.
- You are currently using short-acting opioids, or you are on buprenorphine or methadone treatment.
- You are already enrolled in an outpatient program that offers opioid addiction treatment, including maintenance or abstinence therapies.
- You agree to use birth control (if applicable) during the study and for 30 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a physical device (ADTPM 1) to help manage withdrawal symptoms in people who are dependent on opioids. The goal is to see if the device can safely reduce withdrawal discomfort.
This study tests whether adding tirzepatide, a medication used for weight and blood sugar, to buprenorphine treatment helps people with opioid use disorder. It aims to see if the combination improves outcomes compared to buprenorphine alone.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
This Phase 2 study looks at what opioid withdrawal looks like in the body and whether they can measure it in a meaningful way. You may join if you have an opioid use disorder, can show physical dependence, and are interested in tapering (gradually reducing) opioids under study care.
This study aims to better understand how people experience opioid withdrawal. You will be asked to describe your symptoms, which may help develop a new tool to measure withdrawal more accurately.
Hear when a new Opioid Use Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.